Cargando…
Driving CARs with alternative navigation tools – the potential of engineered binding scaffolds
T cells that are genetically engineered to express chimeric antigen receptors (CAR T cells) have shown impressive clinical efficacy against B‐cell malignancies. In contrast to these highly potent CD19‐targeting CAR T cells, many of those directed against other tumor entities and antigens currently s...
Autores principales: | Zajc, Charlotte U., Salzer, Benjamin, Taft, Joseph M., Reddy, Sai T., Lehner, Manfred, Traxlmayr, Michael W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048499/ https://www.ncbi.nlm.nih.gov/pubmed/32794303 http://dx.doi.org/10.1111/febs.15523 |
Ejemplares similares
-
Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function
por: Salzer, Benjamin, et al.
Publicado: (2020) -
Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives
por: Correll, Christoph U., et al.
Publicado: (2011) -
Alternate Donor Transplantation
por: Hwang, William YK, et al.
Publicado: (2022) -
A conformation-specific ON-switch for controlling CAR T cells with an orally available drug
por: Zajc, Charlotte U., et al.
Publicado: (2020) -
Engineering Strategies to Overcome the Stability–Function
Trade-Off in Proteins
por: Teufl, Magdalena, et al.
Publicado: (2022)